Vieujean, Sophie ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Jacobs, Nathalie ; Université de Liège - ULiège > GIGA > GIGA Immunobiology - Cellular and Molecular Immunology
Fernández-Verdejo, Rodrigo
Fraussen, Judith
Baiwir, Dominique ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques ; Université de Liège - ULiège > GIGA > GIGA Platforms ; Université de Liège - ULiège > Département de chimie (sciences) > Laboratoire de spectrométrie de masse (L.S.M.)
Mazzucchelli, Gabriel ; Université de Liège - ULiège > Département de chimie (sciences) > Laboratoire de spectrométrie de masse (L.S.M.) ; Université de Liège - ULiège > Molecular Systems (MolSys) ; Université de Liège - ULiège > Unités de recherche interfacultaires > GIGA-Technology platforms : Plate-forme protéomique
Reenaers, Catherine ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Van Kemseke, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Louis, Edouard ; Université de Liège - ULiège > GIGA > GIGA Immunobiology - Translational gastroenterology ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Pierre, Nicolas ; Université de Liège - ULiège > Département d'électricité, électronique et informatique (Institut Montefiore) > Informatique
Language :
English
Title :
Higher humoral response in ileal versus colonic Crohn’s disease
Raine T, Danese S. Breaking through the therapeutic ceiling: what will it take? Gastroenterology 2022, 162, 1507-11.
Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, et al. Understanding the therapeutic toolkit for inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2025, 22, 371-94.
Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021, 18, 544-58.
Pierre N, Salée C, Vieujean S, Bequet E, Merli A-M, Siegmund B, et al. Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Aliment Pharmacol Ther 2021, 54, 779-91.
Pierre N, Huynh-Thu VA, Baiwir D, Vieujean S, Bequet E, Reenaers C, et al. Serum proteome signatures associated with ileal and colonic ulcers in Crohn's disease. J Proteomics 2024, 302, 105199.
Lee HH, Yuan Y, Boland BS, Chang JT, Jairath V, Singh S. Efficacy of advanced therapies in achieving remission by disease location in Crohn's disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2025.
Bossuyt P, Bresso F, Dubinsky M, Ha C, Siegel C, Zambrano J, et al. OP40 efficacy of risankizumab induction and maintenance therapy by baseline Crohn's disease location: post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Crohn's Colitis 2022, 16, i048-i048.
Danese S, Sandborn WJ, Colombel J-F, Vermeire S, Glover SC, Rimola J, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. Gastroenterology 2019, 157, 1007-1018.e7.
Rivière P, D'Haens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, et al. Location but not severity of endoscopic lesions influences endoscopic remission rates in Crohn's disease: a post hoc analysis of TAILORIX. Am J Gastroenterol 2021, 116, 134-41.
Peyrin-Biroulet L, Colombel JF, D'Haens G, Dubinsky M, Cao Q, Kligys K, et al. DOP18 efficacy of risankizumab versus ustekinumab by baseline Crohn's disease location: post-hoc analysis of the SEQUENCE head-to-head trial. J Crohn's Colitis 2024, 18, i104-5.
Atreya R, Bojarski C, Kühl AA, Trajanoski Z, Neurath MF, Siegmund B. Ileal and colonic Crohn's disease: does location makes a difference in therapy efficacy? Curr Res Pharmacol Drug Discov 2022, 3, 100097.
Carrasco A, Fernández-Bañares F, Pedrosa E, Salas A, Loras C, Rosinach M, et al. Regional specialisation of T cell subsets and apoptosis in the human gut mucosa: differences between ileum and colon in healthy intestine and inflammatory bowel diseases. J Crohns Colitis 2016, 10, 1042-54.
Bamias G, Kitsou K, Rivera-Nieves J. The underappreciated role of secretory IgA in IBD. Inflamm Bowel Dis 2023, 29, 1327-41.
Baklien K, Brandtzaeg P. Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon. Clin Exp Immunol 1975, 22, 197-209.
Castro-Dopico T, Colombel J-F, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol 2020, 55, 90-8.
Gaifem J, Rodrigues CS, Petralia F, Alves I, Leite-Gomes E, Cavadas B, et al. A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogenic antibodies to mannose glycan. Nat Immunol 2024, 25, 1692-703.
Lee S-H, Turpin W, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, et al. Anti-microbial antibody response is associated with future onset of Crohn's disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk. Gastroenterology 2021, 161, 1540-51.
Mortha A, Remark R, Del Valle DM, Chuang L-S, Chai Z, Alves I, et al. Neutralizing anti-granulocyte macrophage-colony stimulating factor autoantibodies recognize post-translational glycosylations on granulocyte macrophage-colony stimulating factor years before diagnosis and predict complicated Crohn's disease. Gastroenterology 2022, 163, 659-70.
Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 2020, 159, 96-104.
Walker LJ, Aldhous MC, Drummond HE, Smith BRK, Nimmo ER, Arnott IDR, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004, 135, 490-6.
Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005, 128, 2020-8.
Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, et al. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss cohort. Inflamm Bowel Dis 2009, 15, 1358-67.
Han X, Uchida K, Jurickova I, Koch D, Willson T, Samson C, et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology 2009, 136, 1261-71.e3.
Bourgonje AR, Vogl T, Segal E, Weersma RK. Antibody signatures in inflammatory bowel disease: current developments and future applications. Trends Mol Med 2022, 28, 693-705.
Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996, 110, 1810-9.
Nagaishi T, Watabe T, Kotake K, Kumazawa T, Aida T, Tanaka K, et al. Immunoglobulin A-specific deficiency induces spontaneous inflammation specifically in the ileum. Gut 2022, 71, 487-96.
Pierre N, Salée C, Massot C, Blétard N, Mazzucchelli G, Smargiasso N, et al. Proteomics highlights common and distinct pathophysiological processes associated with ileal and colonic ulcers in Crohn's disease. J Crohns Colitis 2020, 14, 205-15.
Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc 2016, 11, 2301-19.
Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 2014, 13, 2513-26.
Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 2016, 13, 731-40.
Wickham H. Ggplot2: Elegant Graphics for Data Analysis, 2nd edn. New York: Springer-Verlag, 2009.
Kong L, Pokatayev V, Lefkovith A, Carter GT, Creasey EA, Krishna C, et al. The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon. Immunity 2023, 56, 444-458.e5.
Baklien K, Brandtzaeg P. Immunohistochemical characterization of local immunoglobulin formation in Crohn's disease of the ileum. Scand J Gastroenterol 1976, 11, 447-57.
Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther 2015, 2, 99-111.
Alberici F, Tedesco M, Popov T, Balcells-Oliver M, Mescia F. Treatment goals in ANCA-associated vasculitis: defining success in a new era. Front Immunol 2024, 15, 1409129.
Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011, 60, 1520-6.
Geffroy-Luseau A, Chiron D, Descamps G, Jégo G, Amiot M, Pellat-Deceunynck C. TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol 2011, 2, 83.
Mei HE, Frölich D, Giesecke C, Loddenkemper C, Reiter K, Schmidt S, et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood 2010, 116, 5181-90.
Kett K, Brandtzaeg P, Fausa O. J-chain expression is more prominent in immunoglobulin A2 than in immunoglobulin A1 colonic immunocytes and is decreased in both subclasses associated with inflammatory bowel disease. Gastroenterology 1988, 94, 1419-25.
Castro CD, Flajnik MF. Putting J chain back on the map: how might its expression define plasma cell development? J Immunol 2014, 193, 3248-55.
